The EluNIR drug-eluting stent made by Medinol performed just as well as the Resolute Integrity or Resolute Onyx stents from Medtronic (NYSE:MDT), according to new clinical study results from an international team of researchers. The randomized clinical trial — conducted by researchers from the U.S., Israel, Canada and the Netherlands — involved 2,221 people and compared […]
Sollis lands $50m for extended-release pain-relief drug
Sollis Therapeutics closed a $50 million round to support a pivotal trial of its non-opioid pain-reliever, according to Ohio-based translator NeuroTechnology Innovations Translator. Deerfield Management led the funding round and was joined by NIT collaborators, including Medtronic (NYSE:MDT), Cardinal Health and Ohio State University. NIT founded Sollis Therapeutics last year to help facilitate the development and commercialization […]
Cardinal Health donates 80,000 Narcan doses to first responders in Appalachia
Cardinal Health today began its donation of more than 80,000 doses of Narcan, a nasal spray designed to reverse opioid overdoses, to community organizations in Ohio, Kentucky, Tennessee and West Virginia. The donation is part of the company’s Opioid Action Program – a pilot program launched last year to bring solutions to first responders, communities […]
Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S.
Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta. The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of […]
Medtech stories we missed: Feb. 3, 2017
From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention. 1. Getinge disappoints on earnings—again Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst […]
Navidea deals NA Lymphoseek rights to Cardinal Health in $310m deal
Navidea Biopharmaceuticals (NYSE:NAVB) said today that it inked a definitive asset purchase agreement with Cardinal Health (NYSE:CAH) for its Lymphoseek product. Dublin, Ohio-based Navidea said it’s due to receive $80 million at closing for the lymphatic mapping and lymph node biopsy product, plus the opportunity for $230 million in milestone payments through 2026. More than $20 […]
